Compare AAME & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AAME | QTTB |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.6M | 44.3M |
| IPO Year | N/A | N/A |
| Metric | AAME | QTTB |
|---|---|---|
| Price | $2.78 | $3.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 19.5K | ★ 163.1K |
| Earning Date | 11-14-2025 | 03-10-2026 |
| Dividend Yield | ★ 0.72% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $208,218,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | ★ 11.99 | N/A |
| 52 Week Low | $1.25 | $1.35 |
| 52 Week High | $3.71 | $6.37 |
| Indicator | AAME | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 61.09 |
| Support Level | $2.67 | $3.65 |
| Resistance Level | $2.80 | $4.14 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 27.76 | 66.67 |
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.